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A large-scale exome array analysis of venous thromboembolism
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Abstract
Although recent genome-wide association studies have identified novel associations for common 
variants, there has been no comprehensive exome-wide search for low-frequency variants that 
affect the risk of venous thromboembolism (VTE). We conducted a meta-analysis of 11 studies 
comprising 8,332 cases and 16,087 controls of European ancestry and 382 cases and 1,476 
controls of African-American ancestry genotyped with the Illumina HumanExome BeadChip. We 
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used the seqMeta package in R to conduct single variant and gene-based rare variant tests. In the 
single variant analysis, we limited our analysis to the 64,794 variants with at least 40 minor alleles 
across studies (minor allele frequency ~ 0.08%). We confirmed associations with previously 
identified VTE loci, including ABO, F5, F11, and FGA. After adjusting for multiple testing, we 
observed no novel significant findings in single variant or gene-based analysis. Given our sample 
size, we had >80% power to detect minimum odds ratios >1.5 and 1.8 for a single variant with 
minor allele frequency of 0.01 and 0.005, respectively. Larger studies and sequence data may be 
needed to identify novel low-frequency and rare variants associated with VTE risk.
INTRODUCTION
Candidate gene studies and genome-wide association studies (GWAS) have identified 
multiple genetic variants that are associated with venous thromboembolism (VTE), a 
condition spanning both pulmonary embolism (PE) and deep vein thrombosis (DVT). The 
majority of genetic variants associated with VTE have been located in genes known to be 
involved in hemostasis, such as ABO, F2, F5, F11, FGG and PROCR (Crous-Bou et al., 
2016). Associations have also been observed for variants located in genes outside known 
hemostasis pathways, such as TSPAN15 and SLC44A2 (Germain et al., 2015), and the exact 
mechanisms by which these genes influence VTE risk have yet to be determined.
Despite these successes, much of the heritability of VTE remains unexplained. A recent 
study based on 3,290 VTE cases and 116,868 controls from the UK Biobank estimated the 
heritability due to genotyped and imputed SNPs to be ~30%(Klarin et al., 2017), and twin 
studies have estimated VTE heritability to be as high as ~ 50%(Heit et al., 2004). However, 
the UK Biobank study also noted that known variants only explain 5% of VTE heritability. 
Thus, additional genetic variants that contribute to VTE risk remain to be discovered.
Recently developed exome arrays(Huyghe et al., 2013) allow for cost-efficient genotyping of 
240,000 coding variants identified through the NHLBI Exome Sequencing 
Project(Tennessen et al., 2012). Based on exome and whole-genome sequencing data from 
9,000 subjects of European ancestry, 2,000 subjects of African ancestry and 500 subjects 
each of Hispanic and Asian ancestry, 240,000 SNPs were selected for inclusion on the 
exome array. To be selected, non-synonymous variants had to be seen at least three times in 
at least two datasets whereas splice and stop variants had to be seen at least two times and in 
at least two datasets. The exome array has proven to be an efficient tool for identifying low-
frequency coding variants associated with blood and cardiovascular traits including: 
hypertension(Surendran et al., 2016, Liu et al., 2016), hematological traits(Eicher et al., 
2016, Chen et al., 2017),(Chami et al., 2016, Mousas et al., 2017), lipid levels(Peloso et al., 
2014), coronary artery disease(Myocardial Infarction et al., 2016), and atrial 
fibrillation(Christophersen et al., 2017). However, no study has published a comprehensive 
investigation of the association between low-frequency exonic variants and VTE.
We hypothesized that exonic, low-frequency genetic variation would be associated with 
VTE. We meta-analyzed exome array genotype data from 11 European and US studies, 
totaling 8,723 VTE cases and 17,563 controls. We conducted both single-variant and gene-
based tests to identify novel genetic variants associated with VTE risk.
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MATERIALS AND METHODS
Study participants
All study participants were either of European or African-American ancestry and came from 
eight US-based cohorts (ARIC, CHS, FHS, HPFS, NHS, NHSII, WGHS and WHI), one US-
based case-control study (HVH), one Norwegian case-control study (Tromsø) and one 
French case-control study (MARTHA)(ARIC Investigators, 1989, Fried et al., 1991, Tell et 
al., 1993, Germain et al., 2011, Hankinson et al., 1995, Tworoger et al., 2006, Ridker et al., 
2008, Solomon et al., 2016, Kannel et al., 1961, Giovannucci et al., 1995, Heckbert et al., 
2008, Women’s Health Initiative Study Group, 1998, Psaty et al., 2009) (Table 1). Details of 
each study have been previously published(ARIC Investigators, 1989, Fried et al., 1991, Tell 
et al., 1993, Germain et al., 2011, Hankinson et al., 1995, Tworoger et al., 2006, Ridker et 
al., 2008, Solomon et al., 2016, Kannel et al., 1961, Giovannucci et al., 1995, Heckbert et 
al., 2008, Women’s Health Initiative Study Group, 1998). Physician-diagnosed VTE was 
identified either through hospital records or validated self-reports, supplemented by review 
of medical records. A detailed description of the study-specific design and characteristics is 
presented in Supplementary Table 1. All participating studies were approved by their 
respective institutional review board and informed consent for genetic analyses was obtained 
from each study participant.
Genotyping and quality control
Genotyping was conducted using either the Illumina HumanExome BeadChip v1.0, Illumina 
HumanExome BeadChip v1.1 or the Illumina HumanCore Exome BeadChip v1.1, 
depending on study. Genotypes from 765 samples from the Tromsø study were obtained 
from exome sequencing rather than genotyping. Genotypes were called using either 
GenomeStudio or Zcall. Each study conducted data cleaning and quality assurance checks 
following a common protocol. Details of study-specific genotype calling and quality control 
can be found in Supplementary Table 1.
We conducted gene set enrichment analysis using the GSEAPreranked algorithm as 
implemented in the GenePattern software and the KEGG, Gene Ontology, and Hallmarks 
pathway sets(Mootha et al., 2003, Subramanian et al., 2005). We applied GSEAPreranked to 
four sets of results (1) Burden test of variants using a broad definition, (2) Burden test of 
variants using a strict definition, (3) SKAT test of variants using a broad definition, (4) 
SKAT test of variants using a strict definition.
One of the included studies (MARTHA) genotyped cases and controls on separate platforms 
(cases were genotyped on Illumina HumanExome 12v.1–2_A and controls were genotyped 
with the Illumina HumanExome 12v.1_A array). We identified a moderate inflation in test 
statistics (λ1000=1.09) in MARTHA for the single variant analysis with MAF>0.005. 
Therefore, we re-meta-analyzed the data while excluding MARTHA, leaving a total of 6,095 
cases and 14,149 controls in a sensitivity analysis.
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Statistical Methods
Each study conducted individual analysis following a common protocol. To avoid type-1 
error inflation(Ma et al., 2013), studies with more than four controls per case randomly 
selected a maximum of four controls for each case (i.e. 1:4 case:control ratio). Those studies 
that performed control selection (ARIC, CHS, FHS, WGHS and WHI) reviewed the 
distribution of age and sex following control selection to ensure roughly equal distributions 
among cases and controls. Each study conducted both single variant and gene-based 
analysis. Association analysis were based on logistic regression adjusting for age, sex, 
principal components and other study-specific variables (as needed). Analyses were 
conducted using the seqMeta(Voorman A, 2017) package in R which produces study-
specific results. Each study sent their study-specific results to the coordinating center at 
Harvard T.H. Chan School of Public Health where the meta-analyses took place.
For single variant analysis, we conducted a meta-analysis of the study-specific score 
statistics based on an additive coding. We limited our analysis to the 64,794 variants that had 
at least 40 minor alleles across studies (corresponding to a minor allele frequency of ~ 
0.08%). Bonferroni correction for the number of variants tested was used to set the 
significance threshold for the analysis corresponding to P<7.7×10−7 (0.05/64,794 variants).
For the gene-based rare variant analyses, we conducted two tests: Weighted-Sum 
Burden(Madsen and Browning, 2009) (WSB) test as implemented in seqMeta(Voorman A, 
2017) and SKAT(Wu et al., 2011). We applied two different sets of criteria to select variants, 
based on coding variant annotation from five prediction algorithms (PolyPhen2, HumDiv 
and HumVar, LRT, MutationTaster and SIFT)(Purcell et al., 2014). The ‘broad’ definition 
included variants with a minor allele frequency (MAF) < 0.01 that were nonsense, stop-loss, 
splice site, as well as missense variants that are annotated as damaging by at least one 
prediction algorithm. The ‘strict’ definition included only variants with a MAF < 0.01 that 
were nonsense, stop-loss, splice-site, as well as missense variants annotated as damaging by 
all five algorithms. For the SKAT analysis, variants were weighted according to the beta 
density function as previously described(Wu et al., 2011). We excluded all genes that had 
fewer than two variants included in the analysis. In total, we tested 15,041 genes using the 
broad definition and 5,749 genes using the strict definition. Bonferroni correction for the 
number of genes and tests performed was used to set the significance threshold for the gene-
based analysis corresponding to P<1.2×10−6 (0.05/41,580 tests [(5,749+15,041) genes × 2 
tests]).
One of the included studies (MARTHA) genotyped cases and controls on separate platforms 
(cases were genotyped on Illumina HumanExome 12v.1–2_A and controls were genotyped 
with the Illumina HumanExome 12v.1_A array. We identified a moderate inflation in test 
statistics (λ1000=1.09) in MARTHA for the single variant analysis with MAF>0.005. 
Therefore, we reran the analysis excluding MARTHA, leaving a total of 6,095 cases and 
14,149 controls in a sensitivity analysis.
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RESULTS
Single Variant Analysis
After excluding all variants with MAC<40 (corresponding to a minor allele frequency of ~ 
0.08%) in the combined study population, single variant meta-analysis showed no sign of 
genomic inflation (λ1000=1.03, Supplementary Figure 1). The strongest association was 
observed for rs635634 at the ABO locus (OR=1.60, 95% CI: 1.52–1.68, P=1.51×10−73). In 
addition, we observed significant associations for previously known genes including the F5, 
FGG, and F11 (Supplementary Table 2). The most strongly associated rare (MAF<0.01) 
variant we observed was rs121918472 (OR=1.93, 95% CI: 1.46–2.56, P=3.55×10−6), a non-
synonymous variant located in the Protein S (PROS1) gene, also known as the p.Ser501Pro 
or PS Herleen mutation, MAF=0.005. This variant is also known to be associated with 
VTE(Suchon et al., 2017). After excluding known loci, only one single variant remained 
significant after adjusting for multiple testing but this signal was driven exclusively by the 
MARTHA study (p=1.96×10−15 when including MARTHA, p=0.37 after excluding 
MARTHA). As the signal at this locus is most likely due to technical issues, we removed it 
from further analysis. No other variant reached genome-wide significance (P<7.7×10−7). 
The strongest sub-threshold association was observed for rs755109, a common (MAF=0.37) 
variant previously associated with thyroid stimulating hormones (OR=1.10, 95% CI: 1.06–
1.16, P=3.31×10−6).
Weighted-Sum Burden (WSB) Rare Variant Analysis
No gene reached the pre-determined significance threshold of P<1.2×10−6 (Figure 1). The 
top three associated genes using the ‘broad’ and ‘strict’ definitions are shown in Table 2 and 
all associations with p<0.01 are shown in Supplementary Tables 3 & 4. The SERPINA10 
gene on chromosome 14 was the third strongest associated gene using the broad (p=0.0002) 
and the strict (p=0.0007) definition. SERPINA10 is expressed primarily in the liver and 
mutations in this gene have previously been linked to VTE(Van de Water et al., 2004, Corral 
et al., 2006).
SKAT Rare Variant Analysis
No gene reached the pre-determined significance threshold of P<1.2×10−6 (Figure 1). The 
top three associated genes using the using the ‘broad’ and ‘strict’ definitions are shown in 
Table 2 and all associations with p<0.01 are shown in Supplementary Tables 5 & 6.
Gene Set Enrichment Analysis
Gene set enrichment analysis based on the results obtained from WSB and SKAT did not 
yield any significant pathway after adjusting for number of pathways tested (all FDR 
q>0.08, data not shown).
DISCUSSION
To assess the contribution of rare coding variation to VTE risk, we combined data from 11 
studies spanning four countries, resulting in exome array data on 8,723 VTE cases and 
17,563 controls. By comparison, the number of cases included in this study is larger than the 
Lindström et al. Page 6
Genet Epidemiol. Author manuscript; available in PMC 2020 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
largest GWAS of VTE published to date(Germain et al., 2015). Beyond known associations, 
we did not observe evidence that additional low-frequency and rare coding variants with 
moderate-to-large effects contribute to VTE risk.
Although our study is the largest genomic study of VTE to date, our ability to identify rare 
variants associated with VTE was limited by low statistical power. Given our sample size, 
we had >80% power to detect minimum odds ratios of 1.56 and 1.81 for a single variant 
with MAF = 0.01 and 0.005, respectively. It is estimated that the exome array includes 97–
98% of non-synonymous variants and 94–95% of stop variants that would have been 
detected in an average genome through exome sequencing (https://genome.sph.umich.edu/
wiki/Exome_Chip_Design). Thus, it is possible that we missed coding variants associated 
with VTE, especially if such variants are particularly rare in individuals who are not affected 
with VTE. Another limitation with this study is the limited contribution of non-European 
populations to our analyses, with 93% of our study population being of European ancestry.
Identifying risk factors for VTE, including genetic risk factors, is of great public health 
importance. VTE affects 1–2/1000 Americans yearly. The incidence has been increasing and 
mortality from PE remains high(Arshad et al., 2017, Heit et al., 2017, Silverstein et al., 
1998, Heit, 2005). The mortality of VTE is greatest in the first 24 hours, and for one-fourth 
of PE patients, the initial clinical presentation is sudden death(Goldhaber et al., 1999, 
Courtney and Kline, 2001, Cohen et al., 2007). Therefore, our ability to improve mortality 
hinges on primary prevention, identifying patients at risk for VTE, and understanding the 
underlying pathophysiology of the disease. Despite the accumulated evidence that genetic 
factors play a major role in the pathophysiology of VTE, only 35% of VTE patients 
undergoing testing for thrombophilia carry a polymorphism known to increase VTE 
risk(Cushman, 2005). Additional efforts to identify genetic variants associated with VTE 
risk are still needed.
The INVENT Consortium is a well-established collaboration of genetic studies of VTE and, 
to our knowledge, our meta-analysis includes data from the vast majority of exome array 
studies of VTE. Additional large studies, potentially including comprehensive sequencing 
data, may be needed to identify novel low-frequency rare coding variants associated with 
VTE. Further research into the genetic basis of VTE is needed to aid in the primary 
prevention of this potentially fatal disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: 
QQ plots for gene burden tests including non-synonymous variants with MAF≤0.01. The 
WSB test using a broad definition of variant inclusion (upper left panel), the WSB test using 
a strict definition of variant inclusion (upper right panel), the SKAT test using a broad 
definition of variant inclusion (lower left panel), the SKAT test using a strict definition of 
variant inclusion (lower right panel).
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Table 1:
Studies included in the VTE exome array analysis.
Ethnicity Study Country Cases Controls
African-American ARIC US 202 807
African-American CHS US 30 120
African-American HVH US 58 181
African-American WHI US 92 368
European ARIC US 433 1,734
European CHS US 112 448
European FHS US 212 848
European HPFS/NHS/NHSII US 2,321 2,301
European HVH US 841 1,788
European MARTHA France 2,628 3,414
European Tromsø Norway 528 526
European WGHS US 610 2,404
European WHI US 656 2,624
Total 8,341 16,087
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Table 2:
Association results for the three strongest associations from the rare variant WSB test.
Variant Inclusion Gene Beta SE P CMAF* # Variants†
Broad FAM71C 3.86 0.871 9.30E-06 0.0002 2
FOXB2 1.56 0.372 2.71E-05 0.0009 4
SERPINA10 0.28 0.077 0.0002 0.017 8
Strict DGAT2 0.64 0.179 0.0004 0.003 4
NUDT12 3.11 0.877 0.0004 0.0002 2
SERPINA10 0.28 0.082 0.0007 0.015 6
*CMAF = Cumulative MAF for SNPs included in the analysis
†Number of variants included in the analysis
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Table 3:
Association results for the three strongest associations from the rare variant SKAT test.
Variant Inclusion Gene Qmeta* P CMAF† # Variants‡
Broad CREB3L1 596343.13 2.59E-05 0.016 7
FAM71C 9844.60 3.65E-05 0.0002 2
PHC3 514613.94 7.76E-05 0.017 10
Strict SRR 37032.58 9.52E-05 0.0007 4
ABCF3 15590.02 0.0002 0.0007 2
DSC1 50186.59 0.0004 0.0014 5
*
The SKAT Q statistic, defined as ∑ jw jU j
2
, where wj is the weight given to SNP j, and U j
2
 is the associated score statistic
†CMAF = Cumulative MAF for SNPs included in the analysis
‡Number of Variants included in the analysis
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